Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
作者： B. Lawrence Riggs , Lynn C. Hartmann
DOI: 10.1056/NEJMRA022219
关键词:
摘要: The selective estrogen-receptor modulators, or SERMs, chemically diverse nonsteroid compounds, have tertiary structures that permit binding to the estrogen receptor. These compounds either agonist antagonist effects, depending on target tissue. This article reviews current information concerning molecular basis of SERM action and tissue-selective agonist–antagonist effects this class medication. also offers a perspective therapeutic uses SERMs compares with nonestrogen alternatives.
elsevier.com
sci-hub.se 参考文章(100)
J.-Y. Reginster, H. W. Minne, O. H. Sorensen, M. Hooper, C. Roux, M. L. Brandi, B. Lund, D. Ethgen, S. Pack, I. Roumagnac, R. Eastell, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis Osteoporosis International. ,vol. 11, pp. 83- 91 ,(2000) , 10.1007/S001980050010
Tamoxifen for early breast cancer: An overview of the randomised trials The Lancet. ,vol. 351, pp. 1451- 1467 ,(1998) , 10.1016/S0140-6736(97)11423-4
Gabriel Hortobagyi, Aman U. Buzdar, Update on endocrine therapy for breast cancer. Clinical Cancer Research. ,vol. 4, pp. 527- 534 ,(1998)
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. The Lancet. ,vol. 360, pp. 817- 824 ,(2002) , 10.1016/S0140-6736(02)09962-2
Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators, None, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA. ,vol. 288, pp. 321- 333 ,(2002) , 10.1001/JAMA.288.3.321
Pamela N. Münster, Aman Buzdar, Kapil Dhingra, Nathan Enas, Lan Ni, Maureen Major, Allen Melemed, Andrew Seidman, Daniel Booser, Richard Theriault, Larry Norton, Clifford Hudis, Phase I Study of a Third-Generation Selective Estrogen Receptor Modulator, LY353381.HCl, in Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 19, pp. 2002- 2009 ,(2001) , 10.1200/JCO.2001.19.7.2002
J.M. Nabholtz, A. Buzdar, M. Pollak, W. Harwin, G. Burton, A. Mangalik, M. Steinberg, A. Webster, M. von Euler, Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial Journal of Clinical Oncology. ,vol. 18, pp. 3758- 3767 ,(2000) , 10.1200/JCO.2000.18.22.3758
Virgil Craig Jordan, Selective estrogen receptor modulation: a personal perspective. Cancer Research. ,vol. 61, pp. 5683- 5687 ,(2001)
T Saarto, C Blomqvist, C Ehnholm, M R Taskinen, I Elomaa, Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. Journal of Clinical Oncology. ,vol. 14, pp. 429- 433 ,(1996) , 10.1200/JCO.1996.14.2.429